Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2009 1
2012 3
2014 1
2017 4
2020 4
2024 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Montalban X, et al. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19. Lancet Neurol. 2024. PMID: 39307151 Clinical Trial.
Relapsing-remitting tumefactive demyelination.
Brandão E, Melo-Pires M, Veira C. Brandão E, et al. Among authors: veira c. JAMA Neurol. 2014 Mar;71(3):366-7. doi: 10.1001/jamaneurol.2013.5. JAMA Neurol. 2014. PMID: 24445489 No abstract available.
Global Vaccine Action Plan Lessons Learned II: Stakeholder Perspectives.
Hwang A, Veira C, Malvolti S, Cherian T, MacDonald N, Steffen C, Jones I, Hinman A, Mantel C. Hwang A, et al. Among authors: veira c. Vaccine. 2020 Jul 14;38(33):5372-5378. doi: 10.1016/j.vaccine.2020.05.048. Epub 2020 Jun 4. Vaccine. 2020. PMID: 32505440 Free PMC article.
Disposing of Excess Vaccines After the Withdrawal of Oral Polio Vaccine.
Wanyoike S, Ramirez Gonzalez A, Dolan SB, Garon J, Veira CL, Hampton LM, Chang Blanc D, Patel MM. Wanyoike S, et al. Among authors: veira cl. J Infect Dis. 2017 Jul 1;216(suppl_1):S202-S208. doi: 10.1093/infdis/jiw572. J Infect Dis. 2017. PMID: 28838168 Free PMC article.
Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines-Lessons Learned From the Global Perspective.
Ramirez Gonzalez A, Farrell M, Menning L, Garon J, Everts H, Hampton LM, Dolan SB, Shendale S, Wanyoike S, Veira CL, Châtellier GMD, Kurji F, Rubin J, Boualam L, Chang Blanc D, Patel M. Ramirez Gonzalez A, et al. Among authors: veira cl. J Infect Dis. 2017 Jul 1;216(suppl_1):S183-S192. doi: 10.1093/infdis/jiw626. J Infect Dis. 2017. PMID: 28838179 Free PMC article.
Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial).
Dávalos A, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Ferro J, Martínez-Vila E, Serena J, Segura T, Cruz VT, Masjuan J, Cobo E, Secades JJ; International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Dávalos A, et al. Lancet. 2012 Jul 28;380(9839):349-57. doi: 10.1016/S0140-6736(12)60813-7. Epub 2012 Jun 11. Lancet. 2012. PMID: 22691567 Free article. Clinical Trial.
16 results